Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
BOSTON, Aug. 15, 2023 -- Galecto, Inc. , a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments for fibrosis and cancer, today... -Today at 07:30 am- MarketScreener